Clinical Trials
11 trialsNCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT05637268 2022-12-05
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05476380 2022-07-27
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04390945 2022-02-03
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Unknown
NCT05183958 2022-01-11
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04286958 2021-12-10
ESCC
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04654403 2021-08-23
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Phase NA Unknown
NCT04512417 2020-08-13
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03671265 2019-01-09
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown